Orchard Therapeutics on Wednesday revealed details regarding the U.S. commercial launch of the newly approved Lenmeldy (atidarsagene autotemcel), giving the one-time gene therapy for metachromatic leukodystrophy a  wholesale acquisition cost of $4.25 million. Source: Biospace 20/3/2024